221 | Humans |
140 | Female |
110 | Male |
108 | Antibodies, Monoclonal, Humanized (therapeutic use) |
104 | Middle Aged |
98 | Arthritis, Rheumatoid (drug therapy) |
81 | Adult |
79 | Treatment Outcome |
75 | Antirheumatic Agents (therapeutic use) |
65 | Aged |
50 | Chronic |
49 | Tocilizumab |
47 | Rheumatology |
47 | Antibodies, Monoclonal, Humanized (adverse effects) |
45 | Rheumatoid arthritis |
45 | Immunomodulator |
38 | Antirheumatic Agents (adverse effects) |
37 | Antibodies, Monoclonal, Humanized (administration & dosage) |
34 | Treatment |
33 | Drug Therapy, Combination |
32 | Severity of Illness Index |
28 | Antibodies, Monoclonal (therapeutic use) |
27 | Immunosuppressive agent |
26 | Tumor Necrosis Factor-alpha (antagonists & inhibitors) |
25 | Retrospective Studies |
25 | Biotherapy |
24 | Glucocorticoids (therapeutic use) |
23 | Biological Products (therapeutic use) |
23 | Antibodies, Monoclonal, Humanized |
22 | Immunosuppressive Agents (therapeutic use) |
22 | Antirheumatic Agents (administration & dosage) |
22 | Antibodies, Monoclonal, Humanized (pharmacology) |
21 | Methotrexate (therapeutic use) |
19 | Interleukin-6 (antagonists & inhibitors) |
18 | Receptors, Interleukin-6 (antagonists & inhibitors) |
18 | Prospective Studies |
18 | Adolescent |
15 | Remission Induction |
15 | Human |
15 | Follow-Up Studies |
15 | Arthritis, Rheumatoid (diagnosis) |
14 | Young Adult |
14 | Interleukin 6 |
14 | Giant Cell Arteritis (drug therapy) |
14 | Arthritis, Rheumatoid (immunology) |
13 | Double-Blind Method |
13 | Child |
13 | Biological Products (adverse effects) |
13 | Antirheumatic agent |
12 | Time Factors |
12 | Arthritis, Rheumatoid (complications) |
12 | Antibodies, Monoclonal (adverse effects) |
12 | Animals |
11 | tocilizumab |
11 | Prognosis |
11 | Prednisone (therapeutic use) |
11 | Disease Progression |
11 | Arthritis, Rheumatoid (blood) |
10 | Still's Disease, Adult-Onset (drug therapy) |
10 | Rituximab |
10 | Rituximab (therapeutic use) |
10 | Risk Factors |
10 | France |
10 | Antineoplastic agent |
10 | Adrenal Cortex Hormones (therapeutic use) |
10 | Abatacept |
10 | Abatacept (therapeutic use) |
9 | Drug Resistance |
9 | Arthritis, Rheumatoid (pathology) |
9 | Arthritis, Juvenile (drug therapy) |
9 | Aged, 80 and over |
8 | Takayasu Arteritis (drug therapy) |
8 | Rituximab (adverse effects) |
8 | Risk Assessment |
8 | Infusions, Intravenous |
8 | Biomarkers (blood) |
8 | Biological Therapy |
7 | Systemic disease |
7 | Recurrence |
7 | Receptors, Interleukin-6 (immunology) |
7 | Radiography |
7 | Polychondritis, Relapsing (drug therapy) |
7 | Injections, Subcutaneous |
7 | Inflammatory joint disease |
7 | Immunologic Factors (therapeutic use) |
7 | Glucocorticoids (administration & dosage) |
7 | Drug Administration Schedule |
7 | Cohort Studies |
7 | Child, Preschool |
7 | Anti-Inflammatory Agents (therapeutic use) |
6 | Spondylarthritis |
6 | Randomized Controlled Trials as Topic |
6 | Polymyalgia Rheumatica (drug therapy) |
6 | Mice |
6 | Methotrexate |
6 | Inflammation |
6 | Biological treatment |
6 | Arthritis, Rheumatoid (metabolism) |
6 | Antirheumatic Agents (pharmacology) |
6 | Anti-Tumor Necrosis Factor-alpha |
6 | Adalimumab |
6 | Adalimumab (therapeutic use) |
5 | rheumatoid arthritis |
5 | Vasculitis |
5 | Uveitis (drug therapy) |
5 | Tumor Necrosis Factor-alpha (metabolism) |
5 | Review |
5 | Phenotype |
5 | Interleukin-6 (immunology) |
5 | Infliximab (therapeutic use) |
5 | Incidence |
5 | Immunocompromised Host |
5 | Glucocorticoids (adverse effects) |
5 | Etanercept (therapeutic use) |
5 | Drug Substitution |
5 | Dose-Response Relationship, Drug |
5 | Diagnosis, Differential |
5 | Cytokine |
5 | Clinical Trials as Topic |
5 | Chronic Disease |
5 | Castleman Disease (drug therapy) |
5 | C-Reactive Protein (metabolism) |
5 | Biological Factors (therapeutic use) |
5 | Behcet Syndrome (drug therapy) |
5 | Arthritis, Rheumatoid (diagnostic imaging) |
4 | Treatment Failure |
4 | Surveys and Questionnaires |
4 | Still's Disease, Adult-Onset (diagnosis) |
4 | Spondylitis, Ankylosing (drug therapy) |
4 | Registries |
4 | Refractory |
4 | Prednisone (administration & dosage) |
4 | Positron-Emission Tomography |
4 | Outcome Assessment, Health Care |
4 | Multivariate Analysis |
4 | Methotrexate (administration & dosage) |
4 | Interleukin-6 (metabolism) |
4 | Interleukin-6 (blood) |
4 | Infection |
4 | Immunoconjugates (therapeutic use) |
4 | Giant cell arteritis |
4 | France (epidemiology) |
4 | Etanercept |
4 | Drug Monitoring (methods) |
4 | Drug Eruptions (etiology) |
4 | Disease Models, Animal |
4 | Disease Management |
4 | Body Mass Index |
4 | Blood Sedimentation |
4 | Biological agent |
4 | Behcet Syndrome (complications) |
4 | Arthritis |
4 | Arthritis, Rheumatoid (therapy) |
4 | Arthritis (drug therapy) |
4 | Antipsoriatic agent |
4 | Antibodies, Monoclonal, Murine-Derived (therapeutic use) |
4 | Antibodies, Monoclonal (administration & dosage) |
4 | Abatacept (adverse effects) |
3 | human |
3 | Uveitis (etiology) |
3 | Tumor necrosis factor |
3 | Tumor Necrosis Factor-alpha (immunology) |
3 | Toxicity |
3 | T-Lymphocytes, Regulatory (pathology) |
3 | Still's Disease, Adult-Onset (pathology) |
3 | Still's Disease, Adult-Onset (complications) |
3 | Still disease |
3 | Spondylarthritis (drug therapy) |
3 | Skin (pathology) |
3 | Scleroderma, Systemic (drug therapy) |
3 | Rheumatic Diseases (immunology) |
3 | Rheumatic Diseases (drug therapy) |
3 | Relapsing polychondritis |
3 | Receptors, Interleukin-6 (drug effects) |
3 | Psoriasis |
3 | Psoriasis (chemically induced) |
3 | Prednisone (adverse effects) |
3 | Polymyalgia Rheumatica (diagnostic imaging) |
3 | Network Meta-Analysis |
3 | Malignant tumor |
3 | Macrophage activation syndrome |
3 | Longitudinal Studies |
3 | Juvenile rheumatoid arthritis |
3 | Joints (physiopathology) |
3 | Joints (pathology) |
3 | Interleukin-6 (physiology) |
3 | Interleukin-6 (genetics) |
3 | Interleukin 1 Receptor Antagonist Protein (therapeutic use) |
3 | Injections, Intravenous |
3 | Inflammation (drug therapy) |
3 | Immunosuppressive Agents (pharmacology) |
3 | Immunomodulation |
3 | Giant Cell Arteritis (therapy) |
3 | Giant Cell Arteritis (immunology) |
3 | Giant Cell Arteritis (diagnosis) |
3 | French |
3 | Etanercept (adverse effects) |
3 | Enzyme-Linked Immunosorbent Assay |
3 | Efficiency |
3 | Drug Hypersensitivity (therapy) |
3 | Cytokines |
3 | Cytokines (metabolism) |
3 | Cytokines (immunology) |
3 | Cytokines (blood) |
3 | Cross-Sectional Studies |
3 | Comorbidity |
3 | Cell Proliferation (drug effects) |
3 | Case-Control Studies |
3 | Biological Therapy (methods) |
3 | Bibliographic review |
3 | Arthritis, Rheumatoid (physiopathology) |
3 | Antirheumatic Agents (pharmacokinetics) |
3 | Antirheumatic Agents (immunology) |
3 | Anti-TNF |
3 | Anakinra |
3 | Adult-onset Still's disease |
3 | Adalimumab (adverse effects) |
2 | uveitis |
2 | treatment |
2 | rapamycin |
2 | polymyalgia rheumatica |
2 | mycophenolate mofetil |
2 | interleukin-6 |
2 | interferon |
2 | infliximab |
2 | inflammation |
2 | eular recommendations |
2 | corticosteroids |
2 | azathioprine |
2 | adalimumab |
2 | Withholding Treatment |
2 | Viral Load (drug effects) |
2 | Vasculitis (drug therapy) |
2 | Ustekinumab (therapeutic use) |
2 | Tumor necrosis factor α |
2 | Tumor Necrosis Factor Inhibitors (therapeutic use) |
2 | Tomography, X-Ray Computed |
2 | Tomography, X-Ray Computed (methods) |
2 | Th17 Cells (pathology) |
2 | Th17 Cells (drug effects) |
2 | Takayasu Arteritis (therapy) |
2 | Takayasu Arteritis (pathology) |
2 | Takayasu Arteritis (immunology) |
2 | Takayasu Arteritis (diagnostic imaging) |
2 | Takayasu Arteritis (diagnosis) |
2 | Takayasu Arteritis (complications) |
2 | T-Lymphocytes, Regulatory (metabolism) |
2 | T-Lymphocytes, Regulatory (drug effects) |
2 | Synovitis (drug therapy) |
2 | Syndrome |
2 | Survival Analysis |
2 | Still's Disease, Adult-Onset (immunology) |
2 | Statistics, Nonparametric |
2 | Skin Neoplasms (chemically induced) |
2 | Sjögren syndrome |
2 | Sjogren's Syndrome (drug therapy) |
2 | Signal Transduction (drug effects) |
2 | Scleroderma, Systemic (complications) |
2 | Sampling Studies |
2 | Salvage Therapy |
2 | Remission Induction (methods) |
2 | Receptors, Interleukin-6 (genetics) |
2 | Pyrimidines (therapeutic use) |
2 | PubMed |
2 | Psoriasis (drug therapy) |
2 | Proportional Hazards Models |
2 | Polymyalgia Rheumatica (diagnosis) |
2 | Polymyalgia Rheumatica (blood) |
2 | Polymorphism, Single Nucleotide |
2 | Polyethylene Glycols (therapeutic use) |
2 | Polychondritis, Relapsing (immunology) |
2 | Polychondritis, Relapsing (complications) |
2 | Peptides |
2 | Peptides, Cyclic (immunology) |
2 | Patient Safety |
2 | Osteoporosis |
2 | Osteocalcin (blood) |
2 | Opportunistic Infections (immunology) |
2 | Opportunistic Infections (diagnosis) |
2 | Opportunistic Infections (chemically induced) |
2 | Neuromyelitis Optica (immunology) |
2 | Neuromyelitis Optica (drug therapy) |
2 | Neoplasms (immunology) |
2 | Neoplasms (chemically induced) |
2 | Molecular Targeted Therapy |
2 | Mice, Inbred C57BL |
2 | Methotrexate (pharmacology) |
2 | Methotrexate (adverse effects) |
2 | Medicine |
2 | Medication Therapy Management |
2 | Maintenance Chemotherapy (methods) |
2 | Macrophage Activation Syndrome (etiology) |
2 | Macrophage Activation Syndrome (chemically induced) |
2 | Lymphohistiocytosis, Hemophagocytic |
2 | Lymphohistiocytosis, Hemophagocytic (complications) |
2 | Lung (diagnostic imaging) |
2 | Logistic Models |
2 | Lipid Metabolism (drug effects) |
2 | Leukocytes, Mononuclear (metabolism) |
2 | Leukocytes, Mononuclear (drug effects) |
2 | Killer Cells, Natural (immunology) |
2 | Kaplan-Meier Estimate |
2 | Joints (drug effects) |
2 | Interleukins (immunology) |
2 | Interleukins (antagonists & inhibitors) |
2 | Interleukin-6 |
2 | Interleukin-6 Receptor alpha Subunit (metabolism) |
2 | Infliximab |
2 | Infliximab (adverse effects) |
2 | Inflammation (pathology) |
2 | Inflammation (immunology) |
2 | Immunosuppressive Agents (adverse effects) |
2 | Immunologic Factors (adverse effects) |
2 | Immunoglobulins, Intravenous (therapeutic use) |
2 | Immunoglobulin Fab Fragments (therapeutic use) |
2 | Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use) |
2 | Hospitals, University |
2 | Herpesvirus 4, Human |
2 | Herpesvirus 4, Human (isolation & purification) |
2 | Herpes zoster |
2 | Health Status |
2 | Glucocorticoids (pharmacology) |
2 | Giant Cell Arteritis (etiology) |
2 | Giant Cell Arteritis (complications) |
2 | Genetic Predisposition to Disease |
2 | Fluorodeoxyglucose F18 |
2 | Flow Cytometry |
2 | Fatigue (etiology) |
2 | Evidence-Based Medicine |
2 | Europe |
2 | Europe (epidemiology) |
2 | Edema (pathology) |
2 | Drugs, Investigational (therapeutic use) |
2 | Drug Therapy, Combination (methods) |
2 | Drug Resistance (drug effects) |
2 | Drug Hypersensitivity (etiology) |
2 | Drug Eruptions |
2 | Desensitization, Immunologic |
2 | Dermatology |
2 | Cytokines (antagonists & inhibitors) |
2 | Crohn Disease (drug therapy) |
2 | Corticosteroid |
2 | Collagen Type II (blood) |
2 | Certolizumab pegol |
2 | Certolizumab Pegol |
2 | Cell Line, Tumor |
2 | Cell Count |
2 | Castleman Disease (pathology) |
2 | Castleman Disease (diagnosis) |
2 | Cartilage, Articular (drug effects) |
2 | Cardiovascular Diseases (prevention & control) |
2 | Cardiovascular Diseases (blood) |
2 | Canakinumab |
2 | Bone and Bones (pathology) |
2 | Biomarkers |
2 | Biomarkers (metabolism) |
2 | Biologics |
2 | Biological Products (pharmacology) |
2 | Bayes Theorem |
2 | B-Lymphocyte |
2 | B cells |
2 | Autoimmunity |
2 | Autoimmune disease |
2 | Autoimmune Diseases (drug therapy) |
2 | Arthritis, Rheumatoid (virology) |
2 | Arthritis, Rheumatoid (psychology) |
2 | Arthritis, Rheumatoid (mortality) |
2 | Arthritis, Rheumatoid (genetics) |
2 | Arthritis, Psoriatic (drug therapy) |
2 | Arthritis, Juvenile (physiopathology) |
2 | Arthritis, Juvenile (immunology) |
2 | Arthritis, Juvenile (diagnosis) |
2 | Arthritis, Infectious (drug therapy) |
2 | Arthritis, Experimental (pathology) |
2 | Arthralgia (physiopathology) |
2 | Arteritis |
2 | Apyrase (metabolism) |
2 | Aortitis (drug therapy) |
2 | Aortitis (diagnostic imaging) |
2 | Antirheumatic Agents (economics) |
2 | Antirheumatic Agents (blood) |
2 | Antiinflammatory agent |
2 | Antigens, CD (metabolism) |
2 | Antibodies, Monoclonal, Humanized (pharmacokinetics) |
2 | Antibodies, Monoclonal, Humanized (immunology) |
2 | Antibodies, Monoclonal, Humanized (blood) |
2 | Antibodies, Monoclonal (pharmacology) |
2 | Antibodies, Monoclonal (immunology) |
2 | Antibodies, Monoclonal (blood) |
2 | Anti-Inflammatory Agents, Non-Steroidal (therapeutic use) |
2 | Anti-Inflammatory Agents, Non-Steroidal (adverse effects) |
2 | Anti-Inflammatory Agents (adverse effects) |
2 | Ankylosing spondylitis |
2 | Amyloidosis (drug therapy) |
2 | Abatacept (administration & dosage) |
1 | visual acuity/drug effect |
1 | uveitis/ drug therapy |
1 | tumor necrosis factor-alpha/antagonist & inhibitor |
1 | tumor necrosis factor-alfa inhibitors |
1 | treatment planning |
1 | treatment outcome |
1 | tomography |
1 | systemic glucocorticoid therapy |
1 | steroid |
1 | sarcoidosis |
1 | risk |
1 | retina/anatomy & histology/drug effect |
1 | remission |
1 | regulatory T cells |
1 | registry regate registry |
1 | receptor |
1 | prospective follow-up |
1 | photometry |
1 | pharmacokinetics |
1 | perimetry |
1 | perforin |
1 | paradoxical reactions |
1 | optimal design |
1 | optical coherence |
1 | non-linear mixed effects model |
1 | nephropathy |
1 | natural killer cells |
1 | multimodal imaging |
1 | monoclonal |
1 | modifying antirheumatic drugs |
1 | methotrexate |
1 | management |
1 | magnetic field |
1 | macular edema |
1 | macular edema/drug therapy |
1 | laser flare photometry |
1 | interleukin |
1 | interleukin-6/antagonist & inhibitor |
1 | interleukin-6 receptor inhibition |
1 | interleukin-6 inhibitor |
1 | infusion-related reactions |
1 | inadequate response |
1 | immunosuppressive agent |
1 | immunosuppressive agent/ therapeutic use |
1 | il-6 receptor subunits |
1 | humanized/ therapeutic use |
1 | hidradenitis suppurativa |
1 | granzyme |
1 | female |
1 | factor-alpha inhibitors |
1 | electroretinography |
1 | drug indication |
1 | drug effect |
1 | diseases |
1 | disease-activity |
1 | dendritic cell |
1 | danish danbio registry |
1 | cytokines |
1 | cytokine |
1 | corticosteroid |
1 | controlled-trial |
1 | clinical-practice |
1 | clinical evaluation |
1 | cerebrospinal fluid |
1 | central nervous system |
1 | cardiovascular risk |
1 | cancer recurrence |
1 | canakinumab |
1 | biologics |
1 | biological therapy |
1 | biological product |
1 | biological agents |
1 | biological DMARDs |
1 | biologic agents |
1 | bayesian fisher information matrix |
1 | apolipoprotein |
1 | antibody |
1 | anti-TNF drug |
1 | anakinra |
1 | aged |
1 | adult |
1 | adult-onset Still\textquoterights disease |
1 | adrenal cortex hormones/therapeutic use |
1 | adipokine |
1 | West |
1 | Voriconazole (therapeutic use) |
1 | Vitrectomy |
1 | Vitiligo (pathology) |
1 | Vitamins (pharmacology) |
1 | Vitamin D (pharmacology) |
1 | Vital Capacity |
1 | Vital Capacity (drug effects) |
1 | Visual Acuity (drug effects) |
1 | Virus Activation |
1 | Virus Activation (immunology) |
1 | Viral hepatitis B |
1 | Vasculitis (physiopathology) |
1 | Vaccination |
1 | Uveitis |
1 | Uveitis (therapy) |
1 | Uveitis (physiopathology) |
1 | Uveitis (pathology) |
1 | Uveal melanoma |
1 | Uveal Neoplasms (pathology) |
1 | Uveal Neoplasms (metabolism) |